Tamoxifen Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Condition:   Breast Cancer Interventions:   Drug: TOL2506;   Drug: Tamoxifen;   Drug: Letrozole tablets;   Drug: Anastrozole Tablets;   Drug: Exemestane Tablets Sponsor:   Tolmar Inc. Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 9, 2022 Category: Research Source Type: clinical trials